semin
studi
dna
vaccin
field
publish
earli
demonstr
administr
plasmid
dna
mice
result
protein
express
encod
transgen
induct
antibodi
respons
protect
pathogen
challeng
follow
nonclin
proof
concept
studi
firstinhuman
phase
clinic
trial
conduct
midtol
normal
healthi
volunt
dna
vaccin
encod
malaria
antigen
respect
sinc
dna
vaccin
infecti
diseas
agent
complet
phase
case
phase
test
includ
anthrax
cmv
dengu
ebola
hepat
b
viru
hepat
c
viru
herp
simplex
human
papillomavirus
season
pandem
influenza
virus
measl
sever
acut
respiratori
syndrom
west
nile
viru
result
earli
clinic
trial
dna
vaccin
candid
indic
favor
safeti
toler
profil
evid
humor
cellmedi
immun
respons
howev
perceiv
need
investig
improv
immunogen
dna
vaccin
result
develop
strategi
enhanc
dna
vaccin
perform
human
strategi
fall
four
nonmutu
exclus
categori
includ
plasmid
design
eg
codon
optim
promot
select
inclus
geneticadjuvantencod
plasmid
formul
eg
polym
cation
liposom
plga
microspher
devic
eg
particlemedi
epiderm
deliveri
electropor
heterolog
primeboost
viral
vector
eg
nyvac
mva
adenoviru
recombin
protein
vical
incorpor
hereaft
vical
develop
cmv
dna
vaccin
candid
util
first
two
strategi
proofofconcept
test
vaccin
phase
trial
complet
vaccin
expect
enter
pivot
phase
trial
sponsor
astella
pharma
incorpor
hereaft
astella
case
studi
present
develop
pathway
vaccin
cytomegaloviru
largest
viru
known
infect
human
initi
predominantli
asymptomat
infect
normal
healthi
individu
persist
life
mostli
latent
infect
without
evid
viremia
cmv
infect
rate
high
worldwid
cmv
seropreval
rate
us
year
old
increas
age
cmv
caus
signific
morbid
mortal
certain
highrisk
situat
includ
congenit
infect
fetus
infect
recipi
hematopoiet
stem
cell
transplant
hct
solid
organ
transplant
sot
treatmentrel
immunosuppress
provid
opportun
cmv
replic
follow
viral
acquisit
reactiv
latenc
antivir
drug
licens
use
transplant
recipi
either
prophylact
preemptiv
upon
evid
viremia
measur
pcr
antigenemia
assay
unfortun
use
first
line
ganciclovirbas
drug
second
line
foscarnet
cidofovir
result
substanti
hematotox
nephrotox
antivir
drug
reduc
incid
cmv
end
organ
diseas
eod
cmv
hct
recipi
prior
licensur
approxim
today
altern
measur
control
cmv
replic
transplant
without
attend
drug
toxic
need
vaccin
repres
one
strategi
numer
phase
phase
trial
conduct
sever
cmv
vaccin
candid
vaccin
yet
licens
indic
vaccin
candid
includ
live
attenu
vaccin
town
strain
townetoledo
chimer
strain
subunit
vaccin
notabl
adjuv
recombin
gb
vector
vaccin
includ
recombin
viral
vector
use
canarypox
alphaviru
platform
plasmid
dna
vaccin
live
attenu
cmv
town
vaccin
deriv
provid
proof
concept
sot
recipi
reduc
cmv
diseas
sever
transplant
howev
provid
efficaci
infect
transplant
recipi
women
expos
cmv
daycar
set
develop
vaccin
appear
depend
upon
implement
strategi
improv
immunogen
begin
recombin
gb
vaccin
produc
cho
cell
develop
test
combin
adjuv
multipl
clinic
studi
ensu
decad
two
recent
random
control
phase
studi
provid
proof
concept
import
gb
protect
cmv
antigen
demonstr
efficaci
decreas
matern
cmv
infect
signific
reduct
durat
viremia
well
durat
antivir
ganciclovir
treatment
cmv
seroneg
recipi
kidney
liver
cmv
donor
despit
result
unclear
whether
gb
adjuv
continu
develop
either
indic
vaccin
approach
viral
vector
gb
andor
complet
phase
test
evid
safeti
immunogen
conceiv
recent
recognit
potenti
import
creat
vaccin
target
pentamer
epitheli
entri
pathway
may
contribut
redirect
vaccin
effort
compani
least
prophylact
vaccin
attempt
block
fibroblast
gbmediat
epitheli
entri
pathway
vical
built
capabl
develop
plasmid
dnabas
product
develop
lead
product
intralesion
immunotherapeut
call
velimogen
aliplasmid
current
evalu
phase
metastat
melanoma
trial
near
complet
earli
product
develop
activ
began
sever
infecti
diseas
target
first
cmv
time
key
function
area
place
design
creat
manufactur
releas
clinic
test
dna
vaccin
product
candid
function
area
expertis
includ
vaccin
research
molecular
biolog
pharmaceut
nonclin
test
manufactur
assay
develop
qualiti
control
qc
qualiti
assur
clinic
research
oper
regulatori
affair
project
plan
manag
describ
initi
cmv
vaccin
target
indic
cmv
hct
recipi
product
develop
timelin
support
activ
vaccin
display
figur
describ
follow
section
vaccin
refer
differ
name
throughout
develop
histori
includ
current
design
vaccin
sinc
licens
astella
cmvseroposit
recipi
allogen
hct
high
attack
rate
cmv
reactiv
follow
transplant
develop
detect
cmv
viremia
within
first
day
increas
risk
develop
cmv
eod
antivir
therapi
initi
due
overal
high
cmvseropreval
rate
cmv
subject
repres
major
subject
undergo
hct
origin
intent
vaccin
normal
healthi
hct
donor
dose
vaccin
seri
prime
boost
cmv
immun
respons
vaccin
recipi
time
transplant
boost
donor
cell
dose
regimen
thought
superior
dose
recipi
time
transplant
potenti
reduct
vaccin
efficaci
due
immunosuppress
medic
requir
posttranspl
initi
test
cmv
hct
recipi
vical
plan
subsequ
evalu
vaccin
product
sot
recipi
organ
cmv
donor
repres
approxim
solid
organ
transplant
highest
risk
cmv
infect
diseas
sever
key
advantag
plasmid
dna
vaccin
offer
rel
vaccin
approach
applic
transplant
recipi
first
consider
safeti
advantag
compar
live
attenu
viru
viral
vector
may
replic
undesir
level
immunosuppress
set
typic
myeloabl
nonmyeloabl
condit
prior
transplant
second
abil
stimul
desir
antivir
tcell
respons
like
live
viru
vaccin
unlik
protein
vaccin
third
repeat
vaccin
administr
would
requir
vaccin
popul
readili
accomplish
plasmid
dna
vaccin
may
difficult
viral
vector
vaccin
typic
invok
antivector
immun
respons
repetit
inject
fourth
dna
vaccin
permit
focus
immun
respons
select
antigen
addit
avoid
immunoevas
cmv
protein
coincident
express
live
attenu
cmv
strain
dna
vaccin
therefor
offer
potenti
tcell
induc
qualiti
reminisc
live
viru
vaccin
safeti
profil
protein
subunit
ideal
vaccin
profil
transplant
recipi
vical
initi
develop
cmv
dna
vaccin
transplant
recipi
first
select
put
protect
cmv
antigen
construct
correspond
plasmid
control
cmv
replic
transplant
recipi
predominantli
attribut
tcell
respons
role
vaccineinduc
antibodi
respons
reduc
cmv
viral
load
could
exclud
could
import
high
risk
sot
recipi
receiv
organ
cmv
donor
base
prevail
knowledg
time
domin
bcell
antigen
recogn
natur
infect
identifi
vaccin
candid
includ
tegument
phosphoprotein
domin
tcell
antigen
envelop
glycoprotein
gb
major
target
neutral
antibodi
comprehens
studi
subsequ
publish
preval
tcell
recognit
essenti
cmv
protein
character
cmv
normal
healthi
subject
result
support
preval
recognit
antigen
final
adopt
transfer
studi
cmvspecif
cell
support
hypothesi
antivir
activ
tcell
control
cmv
replic
transplant
recipi
dna
vaccin
concept
elicit
humor
tcell
mediat
immun
respons
key
cmv
antigen
could
provid
immun
control
earli
allogen
transplant
cmv
recipi
face
highest
risk
cmv
reactiv
eod
name
within
first
day
sequenc
cmv
antigen
encod
plasmid
deriv
laboratoryadapt
cmv
strain
prior
gene
synthesi
clone
protein
sequenc
gb
modifi
silico
secret
form
gb
creat
amino
acid
lieu
fulllength
amino
acid
could
retain
conformationallyintact
epitop
provid
higher
antibodi
titer
nonsecret
form
four
amino
acid
delet
otherwis
fulllength
amino
acid
therebi
elimin
put
kinas
site
mitig
theoret
safeti
concern
express
wildtyp
final
protein
sequenc
establish
codonoptim
use
algorithm
develop
vical
perform
chang
codon
usag
five
amino
acid
frequent
use
codon
us
patent
codonoptim
gene
synthes
clone
vical
plasmid
backbon
contain
human
cmv
promoterenhanc
intron
modifi
rabbit
beta
globin
polyatermin
final
plasmid
nomenclatur
gb
plasmid
respect
synthet
nonion
triblock
poloxam
select
lead
formul
candid
product
poloxam
consist
polyoxypropylen
pop
core
flank
side
polyoxyethylen
poe
block
develop
cytrx
research
laboratori
atlanta
ga
evalu
clinic
studi
proteinbas
vaccin
found
favor
safeti
profil
dose
mginject
direct
relev
dna
vaccin
recent
studi
reveal
inject
rhesu
macaqu
gagencod
plasmid
formul
provid
highest
tcell
respons
compar
formul
follow
boost
express
gag
subsequ
investig
incorpor
cation
surfact
benzalkonium
chlorid
bak
capabl
bind
dna
result
nanoparticl
format
demonstr
increas
tcell
respons
gag
plasmid
formul
compar
dna
dna
alon
bak
concentr
use
inact
ingredi
use
varieti
inject
eg
intramuscular
intraderm
rout
fdaapprov
product
consid
new
raw
materi
combin
bak
selfassembl
stabl
nanoparticl
formul
appear
milki
white
suspens
room
temperatur
becom
clear
temperatur
drop
cloud
point
final
bival
vaccin
formul
design
intramuscular
im
inject
consist
total
plasmid
dose
mg
plasmid
mg
mgml
bak
dissolv
phosphatebuff
salin
pb
store
frozen
formul
provid
key
practic
advantag
compar
altern
cation
lipidbas
formul
undergo
develop
time
higher
dna
dose
could
formul
mgml
singl
vial
formul
possibl
contrast
multivi
format
mgml
reconstitut
dri
lipid
film
mix
cation
lipid
formul
speci
tropism
human
cmv
anim
challeng
model
efficaci
exist
test
human
cmv
vaccin
candid
instead
immunogen
test
conduct
balbc
mice
character
gbbind
serum
igg
level
frequenc
producingt
cell
measur
elispot
assay
overlap
peptid
twodos
threedos
regimen
bival
plasmid
monoval
plasmid
test
without
formul
formul
found
significantli
increas
immun
respons
compar
bival
vaccin
pb
therebi
abrog
immunolog
interfer
encount
combin
prepar
pb
addit
vivo
studi
conduct
conjunct
detail
physic
character
formul
studi
util
plasmid
encod
model
antigen
influenza
nucleoprotein
np
elicit
antibodi
respons
tcell
respons
defin
epitop
follow
threedos
immun
schedul
produc
significantli
higher
respons
dose
dna
alon
np
antibodi
respons
higher
p
respons
defin
class
iirestrict
peptid
higher
p
tcell
respons
class
irestrict
peptid
higher
p
vivo
express
studi
also
conduct
determin
degre
formul
enhanc
deliveri
mice
receiv
singl
inject
plasmid
encod
report
transgen
luciferas
cytoplasm
protein
erythropoietin
secret
protein
compar
dna
alon
provid
increas
luciferas
muscl
increas
erythropoietin
muscl
well
serum
collect
result
support
hypothesi
increas
immunogen
attribut
least
part
enhanc
express
plasmid
deliveri
system
first
two
good
laboratori
practic
glp
compliant
nonclin
studi
conduct
vaccin
repeat
dose
safetytoxicolog
studi
rabbit
receiv
im
inject
interv
mg
mg
mg
dose
product
studi
design
evalu
clinic
sign
includ
inject
site
reaction
draiz
score
bodi
weight
food
consumpt
ophthalmolog
exam
mortal
well
clinic
patholog
includ
hematolog
coagul
clinic
chemistri
panel
antinuclear
antibodi
productrel
chang
evalu
found
except
increas
revers
creatinin
phosphokinas
level
last
inject
minim
moder
inflamm
muscl
skin
encompass
inject
site
larg
resolv
recoveri
period
expect
observ
im
inject
vaccin
second
two
glpcompliant
nonclin
studi
conduct
singl
dose
biodistributionintegr
studi
mice
variou
tissu
sampl
collect
day
inject
bival
product
assess
tissu
distribut
clearanc
kinet
plasmid
time
compar
result
control
plasmid
formul
pb
previous
test
glp
clinic
studi
plasmid
copi
clear
rapidli
inject
day
highest
copi
found
inject
site
muscl
detect
level
spleen
bone
marrow
signific
differ
plasmidcopi
clearanc
two
test
articl
day
integr
studi
conduct
result
support
conclus
risk
plasmid
integr
neglig
pharmacodynam
pharmacokinet
studi
requir
prior
product
vical
acquir
extens
chemistri
manufactur
control
cmc
experi
develop
plasmid
dnabas
product
clinic
test
clinic
test
vical
produc
bulk
drug
substanc
ds
lot
cmv
plasmid
accord
current
good
manufactur
practic
cgmp
plasmid
produc
bacteri
ferment
use
e
coli
strain
kanamycin
select
master
cell
bank
creat
plasmid
specif
puriti
potenc
ident
manufactur
work
cell
bank
deriv
master
cell
bank
use
inocul
overnight
cultur
turn
use
inocul
fermentor
initi
l
later
l
scale
bacteri
cell
past
collect
follow
ferment
process
alkalin
lysi
follow
filtrat
precipit
procedur
follow
downstream
chromatographi
step
final
purifi
bulk
ds
plasmid
adjust
final
dna
concentr
frozen
inprocess
qc
test
conduct
throughout
step
aliquot
final
bulk
ds
lot
place
stabil
program
sampl
submit
releas
test
incorpor
measur
puriti
strengthpot
ident
vical
ds
releas
specif
includ
test
host
e
coli
macromolecul
genom
dna
rna
protein
endotoxin
eumg
dna
percent
supercoil
plasmid
dna
follow
accept
criteria
recommend
fda
guidanc
industri
document
plasmid
dna
vaccin
final
drug
product
dp
manufactur
mix
monoval
bulk
ds
mass
ratio
creat
bival
bulk
ds
formul
bak
asept
condit
result
bulk
dp
challeng
aspect
formul
develop
requir
maintain
temperatur
solut
cloud
point
filtrat
earli
develop
bulk
dp
steril
filter
cloud
point
howev
signific
product
loss
incur
lead
optim
process
prior
phase
steril
filtrat
premix
contain
bak
cloud
point
implement
follow
introduct
sterilefilt
bulk
ds
form
bulk
dp
bulk
dp
asept
fill
glass
vial
store
frozen
sampl
dp
test
releas
well
place
stabil
program
ds
dp
achiev
least
month
stabil
current
dp
releas
test
use
puriti
includ
appear
endotoxin
steril
percent
supercoil
plasmid
dna
particl
size
gener
safeti
test
particul
matter
releas
test
use
ident
includ
ph
total
dna
size
western
blot
product
plasmid
major
ds
dp
releas
assay
standard
ie
applic
regardless
plasmid
howev
one
plasmidspecif
dp
releas
assay
rel
potenc
assay
merit
discuss
import
robust
assay
releas
stabil
test
reversetranscriptas
polymeras
chain
reaction
rtpcr
assay
develop
measur
mrna
express
gb
follow
transfect
bival
product
indic
product
vitro
potenc
messeng
rna
express
plasmid
dna
immedi
biolog
activ
measur
dna
vaccin
deliveri
highlyspecif
assay
design
detect
express
plasmidderiv
transgen
comparison
refer
standard
establish
percent
rel
potenc
rp
test
sampl
rp
assay
incorpor
dp
releas
test
phase
clinic
trial
materi
ctm
lot
well
measur
stabil
lot
lottolot
consist
furthermor
correl
establish
vitro
potenc
vivo
gb
antibodi
respons
mice
sampl
subject
forc
degrad
heat
rp
assay
prove
excel
indic
vivo
potenc
late
vical
complet
appropri
activ
compil
requisit
document
file
investig
new
drug
applic
ind
us
fda
ind
allow
occur
earli
follow
shortli
initi
phase
trial
firstinhuman
clinic
test
denot
multicent
open
label
phase
trial
normal
healthi
adult
cmv
age
year
evalu
safeti
immunogen
bival
vaccin
subject
receiv
im
inject
dna
dose
schedul
dna
dose
acceler
schedul
set
vaccin
well
toler
seriou
advers
event
sae
discontinu
due
vaccinerel
advers
event
ae
frequent
ae
inject
site
pain
myalgia
headach
malais
mild
moder
sever
system
reaction
includ
mild
moder
malais
myalgia
local
reaction
includ
inject
site
pain
indur
swell
erythema
tcell
respons
week
assess
ex
vivo
elispot
assay
use
gb
overlap
peptid
antibodi
respons
gb
assess
indirect
bind
elisa
use
fulllength
recombin
gb
protein
isol
transfect
cho
cell
tcell
andor
antibodi
respons
vaccin
encod
antigen
elicit
cmv
subject
dose
group
respect
suggest
possibl
dose
respons
howev
number
subject
group
power
detect
differ
respons
rate
differ
dose
vaccin
schedul
tcell
respons
detect
cmv
subject
cmv
subject
group
greater
increas
gb
antibodi
level
suggest
antibodi
respons
boost
vaccin
evalu
durat
tcell
respons
cmv
subject
ex
vivo
elispot
assay
perform
week
specimen
subject
inject
schedul
neither
subject
dose
group
respond
assay
earlier
time
point
detect
respons
week
convers
dose
group
subject
detect
respons
includ
subject
tcell
respons
week
addit
subject
detect
respons
week
p
fisher
exact
test
respons
dose
group
week
result
suggest
dose
respons
subject
even
though
dose
respons
establish
initi
evalu
tcell
respons
week
tcell
respons
week
subject
inject
schedul
week
schedul
also
evalu
cultur
elispot
assay
demonstr
abil
vaccineprim
memori
cell
prolifer
produc
exposur
vaccin
encod
antigen
assay
peripher
blood
mononuclear
cell
pbmc
cultur
gb
peptid
recombin
human
day
prior
evalu
elispot
assay
altogeth
vaccineprim
memori
tcell
detect
subject
moreov
memori
tcell
respons
detect
subject
fail
demonstr
tcell
respons
ex
vivo
elispot
assay
time
point
indic
prime
memori
tcell
respons
occur
even
absenc
detect
effector
tcell
respons
second
clinic
trial
multicent
random
doubleblind
placebocontrol
phase
trial
cmv
allogen
hct
recipi
age
year
variou
form
lymphoma
leukemia
accord
origin
trial
protocol
donorrecipi
pair
undergo
hct
plan
enrol
donor
vaccin
prove
logist
impract
protocol
amend
enrol
recipientonli
unpair
arm
subject
random
receiv
dose
pb
placebo
prior
abl
condit
approxim
month
transplant
stratifi
clinic
site
donorrecipi
human
leukocyt
antigen
match
donor
cmv
serostatu
subject
receiv
least
one
dose
includ
safeti
analysi
total
subject
includ
per
protocol
pp
popul
analysi
two
group
wellbalanc
demograph
condit
regimen
donor
related
serostatu
hct
recipi
develop
least
treatmentemerg
advers
event
major
subject
group
develop
sae
studi
statist
differ
group
incid
local
reactogen
higher
group
placebo
group
respect
primarili
due
inject
site
pain
one
sae
vaccin
group
allerg
reaction
resolv
treatment
deem
possibl
relat
sponsor
overal
safeti
profil
group
similar
vaccin
consid
well
toler
trial
primari
efficaci
endpoint
rate
initi
cmvspecif
antivir
therapi
lower
pp
popul
vaccin
group
compar
placebo
group
differ
achiev
statist
signific
p
consider
variabl
exist
among
trial
site
type
local
laboratori
assay
use
detect
cmv
institut
differ
treatment
algorithm
initi
preemptiv
antivir
therapi
contrast
measur
plasma
level
cmv
dna
also
refer
cmv
viremia
use
quantit
pcr
assay
perform
singl
central
laboratori
reveal
statist
signific
differ
two
group
compar
placebo
group
vaccin
group
significantli
lower
occurr
detect
cmv
viremia
p
fewer
cmv
virem
episod
p
longer
time
initi
viremia
p
shorter
durat
viremia
normal
day
studi
p
sever
secondari
endpoint
repres
clinic
manifest
attribut
directli
indirectli
cmv
infect
numer
lower
vaccin
group
compar
placebo
group
achiev
signific
howev
studi
power
detect
differ
endpoint
endpoint
includ
cmv
eod
manifest
pneumonia
gastroenter
overal
mortal
grade
acut
gvhd
sever
chronic
gvhd
posthoc
analysi
composit
endpoint
reveal
differ
favor
vaccin
achiev
statist
signific
p
base
phase
find
describ
section
overal
mortal
select
inclus
primari
endpoint
pivot
phase
trial
prospect
also
includ
sever
endpoint
composit
tcell
respons
gb
hct
recipi
placebo
group
assess
direct
ex
vivo
elispot
assay
level
gbspecif
antibodi
assess
indirect
bind
elisa
tcell
respons
antibodi
level
similar
placebo
recipi
prior
transplant
howev
donorderiv
tcell
respons
gb
evalu
impact
imbal
tcell
respons
rule
tcell
respons
numer
higher
group
rel
placebo
group
time
point
evalu
transplant
despit
variabl
magnitud
respons
trend
toward
signific
differ
respons
day
statist
signific
reach
day
p
respect
wilcoxon
ranksum
test
posthoc
analysi
tcell
respons
ordin
logist
regress
model
use
tcell
respons
ushap
distribut
group
three
categori
defin
pbmc
boundari
time
mean
approxim
pbmc
normal
cmv
individu
use
analysi
respons
treatment
effect
pvalu
day
day
suggest
recipi
significantli
like
high
level
cell
compar
placebo
group
find
reflect
mean
valu
cell
twice
mean
normal
cmv
adult
pbmc
mean
tcell
respons
gb
also
numer
higher
group
placebo
group
time
point
day
howev
differ
time
point
signific
tcell
respons
group
could
enhanc
abl
condit
prior
transplant
may
creat
immunolog
space
rapid
expans
cmv
antigenspecif
tcell
upon
exposur
vaccin
encod
antigen
expans
could
also
occur
either
group
result
exposur
cmv
viral
reactiv
second
posthoc
analysi
use
ordin
logist
regress
model
tcell
respons
censor
occurr
viremia
elimin
influenc
exposur
cmv
tcell
respons
group
still
higher
placebo
group
treatment
effect
p
suggest
compar
higher
respons
group
independ
cmv
viremia
like
due
vaccin
furthermor
subject
cmv
viremia
day
tcell
respons
day
significantli
higher
group
placebo
group
p
wilcoxon
ranksum
test
indic
diverg
respons
two
group
begin
earli
vaccin
regimen
provid
protect
cmv
reactiv
time
period
cmv
viremia
occur
geometr
mean
gb
antibodi
level
significantli
higher
group
placebo
group
fourth
inject
gb
antibodi
level
show
trend
toward
signific
day
reach
signific
day
p
respect
wilcoxon
ranksum
test
late
diverg
gb
antibodi
level
two
group
compar
earli
diverg
tcell
respons
may
reflect
differ
persist
antibodi
cell
ablat
kinet
recoveri
transplant
design
global
phase
trial
sponsor
astella
pharma
global
develop
inc
vical
collabor
recent
regist
wwwclinicaltrialsgov
offici
titl
protocol
random
doubleblind
placebocontrol
phase
trial
evalu
protect
efficaci
safeti
therapeut
vaccin
cytomegaloviru
cmv
seroposit
recipi
undergo
allogen
hematopoiet
cell
transplant
hct
subject
random
receiv
pb
placebo
primari
efficaci
endpoint
trial
overal
mortal
one
year
posttransplant
safeti
hct
recipi
also
monitor
trial
anticip
enrol
subject
analyt
divid
two
part
part
enrol
subject
part
enrol
subject
part
use
evalu
adequaci
primari
endpoint
necessari
modifi
primari
endpoint
specifi
part
trial
enrol
subject
approxim
hct
center
north
america
europ
asia
australia
anticip
complet
septemb
product
dp
test
phase
phase
trial
improv
cmcrelat
process
refin
analyt
test
method
assay
specif
identifi
implement
prior
phase
test
furthermor
dp
lot
size
suffici
phase
phase
ctm
increas
scale
manufactur
procedur
meet
ctm
demand
phase
process
improv
enhanc
manufactur
effici
lottolot
consist
streamliningsimplifi
procedur
upgrad
equip
enrich
product
yield
assay
underw
refin
result
increas
sensit
precis
eas
use
reagent
stabil
avail
plasmidspecif
ds
dp
releas
assay
valid
prepar
use
phase
cmcrelat
chang
submit
fda
current
ind
timelin
figur
integr
key
activ
describ
illustr
typic
unanticip
factor
impact
product
develop
timelin
reason
repres
time
frame
ensu
product
concept
complet
phase
test
accordingli
indic
favor
safeti
profil
demonstr
immunogen
human
vital
first
stage
vaccin
program
contrast
phase
trial
hct
recipi
took
extend
period
time
enrol
larg
due
novelti
approach
inherentlycomplex
natur
conduct
vaccin
trial
subject
underli
condit
treatmentassoci
morbid
furthermor
describ
section
origin
premis
vaccin
donor
due
limit
time
donor
avail
prior
transplant
prove
impract
arm
discontinu
leav
recipientonli
arm
open
strategi
mitig
risk
inher
product
develop
optim
assay
valid
activ
delay
late
phase
trial
ultim
agreement
fda
addit
discuss
global
regulatori
agenc
europ
asia
requir
thorough
frequent
commun
defin
accept
endpoint
licensur
vical
licens
program
astella
period
joint
particip
group
regulatori
discuss
phase
trial
endpoint
aspect
product
develop
histori
could
shorten
small
biotechnolog
compani
vical
typic
encount
resourc
constraint
risk
manag
play
import
role
time
activ
fortun
partnership
continu
develop
provid
tremend
opportun
advanc
firstinclass
therapeut
cmv
vaccin
toward
product
licensur
proof
concept
find
bival
cmv
vaccin
hct
recipi
provid
support
test
product
sot
recipi
random
doubleblind
placebocontrol
phase
trial
plan
recipi
receiv
kidney
transplant
either
live
donor
deceas
donor
cmv
highest
risk
group
among
sot
recipi
experienc
cmv
diseas
final
cmv
prophylact
vaccin
prevent
congenit
cmv
infect
would
tremend
public
health
impact
howev
develop
vaccin
indic
requir
consider
resourc
due
longer
clinic
develop
pathway
potenti
high
number
subject
clinic
trial
furthermor
clinic
endpoint
requir
licensur
vaccin
final
recent
receiv
discuss
govern
academia
manufactur
vical
initi
develop
prophylact
congenit
cmv
vaccin
develop
differ
product
formul
cation
lipid
adjuv
call
combin
gb
plasmid
recent
publish
nonclin
immunogen
glp
safeti
studi
given
enorm
scope
develop
vaccin
develop
would
ideal
proceed
partnership
larg
pharma
compani
parallel
addit
research
ongo
identifi
one
addit
plasmid
express
cmv
gene
section
potenti
inclus
vaccin
encourag
proof
concept
result
difficult
hct
recipi
popul
provid
optim
develop
cmv
vaccin
addit
unmet
need
